Chronicle Journal: Finance

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Protagonist Therapeutics Inc (NQ: PTGX )

28.11 USD -1.24 (-4.22%)
Official Closing Price Updated: 4:01 PM EST, Mar 4, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 547,155
Open 28.92
Bid (Size) 28.11 (1)
Ask (Size) 28.18 (18)
Prev. Close 29.35
Today's Range 27.54 - 29.71
52wk Range 5.300 - 31.58
Shares Outstanding 21,203,892
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Protagonist Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results
Protagonist Therapeutics, Inc. (Nasdaq: PTGX), today announced it will host a conference call and webcast on Wednesday, March 10 at 4:30 pm ET/1:30 pm PT to discuss its fourth quarter and full year... 
From PR Newswire
Protagonist Therapeutics to Participate in the H.C. Wainwright Global Life Sciences Conference
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and will host one-on-one meetings... 
From PR Newswire

Performance

YTD
+43.42%
+43.42%
1 Month
+35.60%
+35.60%
3 Month
+27.83%
+27.83%
6 Month
+28.92%
+28.92%
1 Year
+252.26%
+252.26%

More News

Read More
Protagonist Therapeutics Reports Granting of Inducement Award
From PR Newswire
Protagonist Therapeutics to Participate in the SVB Leerink Virtual 10th Annual Global Healthcare Conference
From PR Newswire
Protagonist Therapeutics Reports Granting of Inducement Award
From PR Newswire
Protagonist Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
From PR Newswire
Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-235 (JNJ-77242113)
From PR Newswire
Protagonist Therapeutics, Inc. Announces Closing of $115 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
From PR Newswire
Protagonist Therapeutics, Inc. Announces Pricing of $100 Million Public Offering of Common Stock
From PR Newswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Tags EYEN BCTX Markets
From Benzinga
Stocks Flashing Renewed Technical Strength: Protagonist Therapeutics
From Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

© Copyright 2015, Chronicle Journal, Thunder Bay, ON. Powered by BLOX Content Management System from TownNews.com. [Terms of Use | Privacy Policy]